THE OVERVIEW AT DAA TREATMENT OF CHRONIC HEPATITIS C IN POLAND
DOI:
https://doi.org/10.11603/1681-2727.2018.1.8666Keywords:
HCV, chronic infection, DAA, Polish recommendations.Abstract
The goal of therapy is eradication of HCV infection; stop or reverse histological changes; reduce the risk of hepatocellular carcinoma development and transmission of the infection to other individuals. According to the Recommendations of Polish Group of Experts for HCV each adult patient with chronic HCV infection should receive DAA (direct acting agents) treatment; except patients with limited live expectancy due to other serious comorbidities.
If access to therapy is restricted; priority should be given to patients whose HCV infection can lead to an unfavorable outcome of the disease within a short time frame; to individuals with liver cirrhosis; rapidly progressing liver fibrosis; extrahepatic manifestations of HCV infection; chronic kidney diseases; patients before and post organ transplantation.
Recommendations provide guidelines to select optimal regimen; assessment of liver fibrosis; treatment efficacy; dealing with resistance to direct acting antivirals; monitoring for hepatocellular carcinoma; management of HBV/HCV coinfection and drug interactions. It contains also advice on treatment for patient’s with renal failure; liver transplant and hepatic decompensation; as well as retreatment of patients which failed interferon free therapy. Moreover; specific recommendations of management patients infected with different genotypes with currently reimbursed regimens or those expected to become available shortly in Poland are also included.
References
Halota; W.; Flisiak; R.; Juszczyk; J.; Małkowski; P.; Pawłowska; M.; Simon; K.; & Tomasiewicz; K. (2017). Recommendations for the treatment of hepatitis C in 2017. Clin. Exp. Hepatol.; 3 (2); 47-55.
Flisiak; R.; Halota; W.; Horban; A.; Juszczyk; J.; Pawlowska; M.; & Simon; K. (2011). Analysis of risk factors related to HCV infection in Poland. Eur. J. Gastroenterol. Hepatol.; 23; 1213-1217.
Flisiak; R.; Halota; W.; Tomasiewicz; K.; Kostrzewska; K.; & Razavi; H.A. (2015). Forecasting the disease burden of chronic hepatitis C virus in Poland. Eur. J. Gastroenterol. Hepatol.; 27; 70-76.
Flisiak; R.; Pogorzelska; J.; Berak; H.; Horban; A.; Orłowska; I.; Simon; K.; ... Mazur; W. (2016). Prevalence of HCV genotypes in Poland – the EpiTer study. Clin. Exp. Hepatol.; (2); 144-148.
EASL (2017). Recommendations on Treatment of Hepatitis C 2016. J. Hepatology; 66; 153-194.
Jaroszewicz; J.; Flisiak-Jackiewicz; M.; Lebensztejn; D.; Flisiak; R. (2015). Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis. Expert Opin. Investig. Drugs; 24; 1229-1239.
HEP Drug Interaction Checker. [E-resource]. Retrieved from: www.hep-druginteractions.org
AST to Platelet Ratio Index (APRI) Calculator. [E-resource]. Retrieved from: www.hepatitisc.uw.edu/page/clinical-calculators/apri
Kobayashi; M.; Suzuki; F.; Fujiyama; S.; Kawamura; Y.; Sezaki; H.; Hosaka; T.; ... Kumada H. (2017). Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. J. Med. Virol.; 89; 476-483.
ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER; CO12 CirVir and CO23 CUPILT cohorts). (2016). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J. Hepatol.; 65; 734-740.
Calvaruso; V. (2017). Early occurence of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis treated with direct-acting antivirals (DAAs). EASL HCC Summit; Geneva; 2-5 February; COO3.
Cavaletto; L. (2017). Comparison between de-novo occurence and recurrence of hepatocellular carcinoma (HCC) after direct-acting antivirals (DAAs) in cirrhotic patients with hepatitis C: A real-life cohort study. EASL HCC Summit; Geneva; 2-5 February; PIO.05.
Kolly; P. (2017). Hepatocellular carcinoma after direct antiviral agent treatment: A European Multicenter study. EASL HCC Summit; Geneva; 2-5 February; PII.09-YI.
Castano; A. (2017). Alpha fetoprotein (AFP) levels before and after sustained virological response with direct-acting antivirals (DAAs) in patients with liver cirrhosis due to hepatitis C virus (HCV). EASL HCC Summit; Geneva; 2-5 February; PI3.04-YI.
Conti; F.; Buonfiglioli; F.; Scuteri; A.; Crespi; C.; Bolondi; L.; Caraceni; P.; ... Lenzi; M. (2016). Early occurence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated direct-acting antivirals. J. Hepatol.; 65; 727-733.
Reig; M.; Mariño; Z.; Perelló; C.; Iñarrairaegui; M.; Ribeiro; A.; Lens; S.; ... Darnell A. (2016). Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J. Hepatol.; 65; 719-726.
AASLD/IDSA (Sep 2016). Recommendations for Testing; Managing; and Treating Hepatitis C updated.
Ende; A.R.; Kim; N.H.; Yeh; M.M.; Harper; J.; Landis; C.S. (2015). Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J. Med. Case Rep.; (9); 164.
Calleja; J.L.; Crespo; J.; Rincón; D.; Ruiz-Antorán; B.; Fernandez; I.; Perelló; C.; ... Mariño; Z. (2017). Effectiveness; safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real world cohort. J. Hepatol.; doi: 10.1016/j.jhep.2017.01.028. [Epub ahead of print].
Viekirax (2015). Summary of Product Characteristics. Maidenhead; United Kingdom AbbVie Ltd.
Exviera; Summary of Product Characteristics.
Harvoni; Summary of Product Characteristics.
Flisiak; R.; Łucejko; M.; Mazur; W.; Janczewska; E.; Berak; H.; Tomasiewicz; K.; ... Piekarska; A. (2017). Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study. Adv. Med. Sci.; 62; 387-392.
Daklinza; Summary of Product Characteristics. packageinsert.bms.com.
Kumada; H.; Suzuki; Y.; Ikeda; K.; Toyota; J.; Karino; Y.; Chayama; K.; ... Hughes; E. (2014). Daclatasvir plus Asunaprevir for chronic HCV genotype 1b infection. Hepatology; 59; 2083-2091.
Manns; M.; Pol; S.; Jacobson; I.M.; Marcellin; P.; Gordon; S.C.; Peng; C.Y.; ... Noviello; S. (2014) All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational; phase 3; multicohort study. Lancet; 384; 1597-1605.
Zepatier; Summary of Product Characteristics.
Epclusa; Summary of Product Characteristics.
Sovaldi; Summary of Product Characteristics. htt//www.ema.europa.eu.
Cornberg; M.; Petersen; J.; Schober; A.; Mauss; S.; Böker; K.H.; Link; R.; ... Niederau C. (2017). Real-world use; effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. Aliment. Pharmacol. Ther.; 45; 688-700.
Pegasys; Summary of Product Characteristics.
Downloads
Published
How to Cite
Issue
Section
License
Journal Infectious Disease (Infektsiini Khvoroby) allows the author(s) to hold the copyright without registration
Users can use, reuse and build upon the material published in the journal but only for non-commercial purposes
This journal is available through Creative Commons (CC) License BY-NC "Attribution-NonCommercial" 4.0
